These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8934724)

  • 1. Infusional chemotherapy with new drugs: taxanes, vinorelbine and topoisomerase I inhibitors.
    Dieras V; Pouillart P
    J Infus Chemother; 1995; 5(4):191-2. PubMed ID: 8934724
    [No Abstract]   [Full Text] [Related]  

  • 2. The suitability of selected new anticancer agents for infusional therapy and the effects of others on infusional therapy practices.
    Rowinsky EK
    J Infus Chemother; 1995; 5(4):173-8. PubMed ID: 8934721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs.
    Holden JA
    Ann Clin Lab Sci; 1997; 27(6):402-12. PubMed ID: 9433537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
    Pourquier P; Pommier Y
    Bull Cancer; 1998 Dec; Spec No():5-10. PubMed ID: 9932078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging DNA topisomerase inhibitors as anticancer drugs.
    Denny WA
    Expert Opin Emerg Drugs; 2004 May; 9(1):105-33. PubMed ID: 15155139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Topoisomerase I inhibitors].
    Bornkessel B
    Med Monatsschr Pharm; 1997 May; 20(5):114-6. PubMed ID: 9221294
    [No Abstract]   [Full Text] [Related]  

  • 9. [Inhibitors of DNA topoisomerases].
    Andoh T
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1526-35. PubMed ID: 9309151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy.
    Cragg GM; Newman DJ
    J Nat Prod; 2004 Feb; 67(2):232-44. PubMed ID: 14987065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?
    Saltz L; Janik JE
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-26-S5-30. PubMed ID: 9122740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
    Garcia-Carbonero R; Supko JG
    Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.
    Sharma S; Kemeny N; Schwartz GK; Kelsen D; O'Reilly E; Ilson D; Coyle J; De Jager RL; Ducharme MP; Kleban S; Hollywood E; Saltz LB
    Clin Cancer Res; 2001 Dec; 7(12):3963-70. PubMed ID: 11751488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro.
    Zhao R; al-Said NH; Sternbach DL; Lown JW
    J Med Chem; 1997 Jan; 40(2):216-25. PubMed ID: 9003520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diflomotecan. Ipsen.
    Osheroff N
    IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel camptothecin derivatives as topoisomerase I inhibitors.
    Basili S; Moro S
    Expert Opin Ther Pat; 2009 May; 19(5):555-74. PubMed ID: 19441934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumour drug design: DNA-binding ligands, which inhibit the topoisomerase I.
    Pindur U; Lemster T
    Pharmazie; 1998 Feb; 53(2):79-86. PubMed ID: 9540103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells.
    Bevins RL; Zimmer SG
    Cancer Res; 2005 Aug; 65(15):6957-66. PubMed ID: 16061681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.